The Compound · News
What is CX11?
A biotech most people have never heard of just posted real Phase 2 numbers for another oral GLP-1 pill. CX11 is not going to beat orforglipron or aleniglipron to market, but the trial data is specific enough to be worth understanding now, before the bigger sites catch up.
What CX11 is and who makes it
CX11 is an oral small-molecule GLP-1 receptor agonist in development for obesity, overweight, and type 2 diabetes. Corxel Pharmaceuticals holds the rights outside China, which it acquired from Vincentage Pharma in December 2024. Vincentage kept the China rights and already ran a Phase 3 program there. Corxel is running the separate US and global track, and just reported its own Phase 2 data.
Corxel is not a name most people recognize, and that is part of the story. Every press outlet that has covered CX11 so far is trade or industry press: BioSpace, Clinical Trials Arena, Medscape. No consumer health site has written it up yet. That gap is why this is worth covering now rather than waiting for a bigger story to force the issue.
Why "small molecule" is the detail that matters
The distinction between a peptide and a small molecule GLP-1 drug determines how the pill has to be taken. Oral semaglutide is a peptide, and peptides get broken down by stomach acid, so Novo Nordisk built a special absorption-enhancing formulation around it. Even with that engineering, oral semaglutide requires a strict fasting window: take it with a small amount of water, then wait 30 minutes before eating, drinking, or taking other medication.
Small molecules like orforglipron, aleniglipron, and now CX11 survive digestion without that workaround. No fasting window, no timing rules, take it like any other daily pill. For a fuller rundown of how that split shaped the oral GLP-1 category, see the oral GLP-1 pill guide.
What the Phase 2 trial found
The US Phase 2 trial (NCT07011797) enrolled 246 adults with obesity (BMI 30 or above) or overweight with at least one weight-related condition. Five arms, randomized evenly, received CX11 at 120mg, 160mg, or 200mg (with two different titration speeds tested at the top dose), or placebo, once daily for 36 weeks.
Corxel's headline claim was that weight loss was still climbing at week 36 with no sign of flattening out, which is the pattern regulators and investors look for as a signal that longer trials will keep producing results rather than topping out early.
Safety and tolerability so far
The side effect profile follows the pattern every GLP-1 drug shares: nausea, vomiting, and GI discomfort, concentrated early in treatment and during dose increases. Corxel described its vomiting rate, 12 to 16%, as notably low for the class. About 5% of participants dropped out specifically because of GI side effects.
The company also reported no liver safety signals across the more than 1,500 people who have now taken CX11 between its China and US programs, a meaningfully larger safety database than a typical first US Phase 2 trial would have on its own, since it draws on Vincentage's earlier China work.
How CX11 compares to the other oral GLP-1s
Three data points, with the same caveat that applies to every early-stage comparison in this category: different trials, different doses, different durations, different populations. None of this is a head-to-head.
| Drug | Fasting | Weight loss | Phase | Status |
|---|---|---|---|---|
| Orforglipron | None | 12.4% | Phase 3 | FDA-approved |
| Aleniglipron | None | 16.3%* | Phase 2 | Not approved |
| CX11 | None | 11.5% | Phase 2 | Not approved |
*Placebo-adjusted, 44 weeks. Orforglipron is total weight loss in Phase 3. CX11 is total weight loss at 36 weeks. Figures are not directly comparable across trial phases or designs. See what is aleniglipron for the full aleniglipron breakdown.
CX11's 11.5% is the lowest of the three so far, but it is also the earliest readout and the shortest trial duration, and Corxel's own framing is that the curve had not leveled off. Whether that translates into a competitive Phase 3 number is exactly what the next few years of trials will decide.
What is next for CX11
Corxel says it plans to discuss pivotal Phase 3 trial design with the FDA and EMA, with a global registrational trial targeted to start in early 2027, building on the Phase 3 program Vincentage already completed in China. A Phase 3 obesity trial for a drug in this class typically runs 60 to 80 weeks before results are read out, and regulatory review after that adds another year or more.
That puts a realistic earliest approval somewhere around 2030, and that is only if every remaining trial succeeds. Phase 2 results, even encouraging ones, do not reliably predict Phase 3 outcomes in this drug class. For context on how the broader next-generation obesity drug pipeline is shaping up, see what is retatrutide, which is much further along in Phase 3 with a substantially higher efficacy ceiling.
Current status
- Global Phase 3 trial targeted to start early 2027
- Not FDA-approved. No legal source for CX11 today
- Phase 2 topline results announced June 2026
- 11.5% weight loss at 36 weeks, highest dose arm, still trending down
- Developer: Corxel Pharmaceuticals; China rights held by Vincentage Pharma
For the two oral GLP-1 pills you can actually get a prescription for today, see the oral semaglutide vs orforglipron comparison.
